Viridian Therapeutics’ elegrobart scored another Phase 3 win in chronic thyroid eye disease, rebuilding investor confidence after earlier results disappointed. Analysts framed the new data as more competitive with Amgen’s Tepezza, setting the stage for a potential regulatory path. The report highlights how an additional Phase 3 readout can alter commercial expectations by sharpening efficacy positioning in an indication with strong benchmark effects. The focus now shifts to how Viridian packages the chronic-population data for regulator review.